Status:
COMPLETED
Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.
Lead Sponsor:
Teikoku Seiyaku Co., Ltd.
Collaborating Sponsors:
ClinSearch
SocraTec R&D GmbH
Conditions:
Healthy
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
This study is a multi center, multiple dose, open label trial to evaluate the adhesion of TK-254RX in healthy volunteers. The primary purpose of this study is to evaluate the adhesion of TK-254RX. Sec...
Eligibility Criteria
Inclusion
- age: 18 to 64 years
- good state of health
- non-smoker or ex-smoker for at least 3 months
- written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial
Exclusion
- The following must not apply:
- any injury of body which may induce the restriction of body movement
- excessively hairy skin at application site
- current skin disorder or shaving hair at application site
- history of excessive sweating/hyperhidrosis inclusive of application site
- participation in a clinical study within 30 days before inclusion in the study or concomitantly
- drug or alcohol abuse in the opinion of the investigator
- pregnant and lactating women
- women of child-bearing potential who do not agree to apply highly effective contraceptive methods
- known hypersensitivity to active ingredient, its racemate or one of the excipients of the TK-254RX
- existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
- existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
- known liver or kidney insufficiency
- existing gastrointestinal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
- history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
- systolic blood pressure \< 90 or \> 139 mmHg
- diastolic blood pressure \< 60 or \> 89 mmHg
- pulse rate \< 50 bpm or \> 90 bpm
- subjects who use any impermissible medication
Key Trial Info
Start Date :
September 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06042192
Start Date
September 14 2023
End Date
December 13 2023
Last Update
April 12 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Practice Ebert
Brühl, Germany
2
Medical practice Pabst
Fürstenfeldbruck, Germany
3
Medical practice Gastl
Gilching, Germany
4
Medical Pracitice Schaale/Bücheler
Rheinbach, Germany